Loading clinical trials...
Loading clinical trials...
Silodosin is compared to placebo to determine if it is safe and effective for the treatment of nighttime urination (nocturia) in men with BPH
Bring this clarity to your next appointment.
Keep all your medical notes and next steps in one place.
Lead Sponsor
Watson Pharmaceuticals
NCT05574244 · Benign Prostatic Hyperplasia
NCT03297281 · Benign Prostatic Hyperplasia, Anticoagulant Adverse Reaction
NCT07016620 · Benign Prostatic Hyperplasia (BPH)
NCT03354416 · Prostatic Cancer, Prostatic Neoplams, and more
NCT06312722 · Benign Prostatic Hyperplasia
Watson Investigational Site
Huntsville, Alabama
Watson Investigational Site
Laguna Hills, California
Watson Investigational Site
San Diego, California
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions